Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Search Research Studies
Search Results: Treatment + BRCA + Prostate Cancer (13 results)
Cancer treatment study for people with advanced solid tumors
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.
Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC). This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.
High-risk localized prostate cancer
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.
Treatment study for people with advanced solid tumors
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHK1, CHK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.
Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene
Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair
This study is comparing three different treatments for men with metastatic castration-resistant prostate cancer, (mCRPC) who also have an inherited mutation or a tumor mutation in a gene that affects DNA damage repair. The study is open to men with inherited mutations found on genetic testing or tumor mutations in one of the following genes: ATM, BRCA1, BRCA2, FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A.
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene
Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)
The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L.
Advanced ovarian, breast, prostate or pancreatic cancer
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Advanced solid tumors
Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)
This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.
Advanced solid tumors
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Advanced solid tumors
Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations
This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.